Abstracts ponent summary score as well as on the general health, vitality, social functioning and role emotional domains of the SF-36 (P Ͻ 0.05). CONCLUSIONS: The results of this interim analysis suggest that TM patients have a lower quality of life than patients with EM.
Patients who received at least one abortive migraine prescription during July 1998 through December 1998 and who had been continuously enrolled in a large west coast health maintenance organization (HMO) for that period were identified through the HMO pharmacy prescription database and screened for eligibility criteria. Eligible HMO patients were those who did not have any sensitivity nor contraindications to receiving Excedrin-migraine. Patients from four medical groups in Southern California were asked to participate based on the groups' higher than network migraine prescription utilization. Physician groups who participated in the program consisted mainly of primary care physicians or family practitioners and a small proportion of neurologists. OBJECTIVE: To evaluate the effects of an over-the-counter (OTC) migraine medication on patient quality-of-life two and four months after initiation therapy. METHODS: This was an observational study where enrolled patients received a one month supply of Excedrin-migraine samples along with a self-administered SF-36 questionnaire to complete at baseline, months two and four. All data were analyzed using SAS statistical software (version 6.12) with ␣ set at 0.05. RESULTS: Results at month four indicated improvements in both MCS (P Ͻ 0.05) and PCS scores. In addition, there were improvements in seven of the eight domains of the SF-36 with Role Physical, Bodily Pain, Vitality and Social Functioning being significantly different (P Ͻ 0.05). CONCLUSION: In the four months after initiation of the OTC migraine program, quality-of-life scores improved for the migraineurs enrolled in the study.
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MODELING LENGTH OF PRESCRIPTION THERAPY FOR DEPRESSION PATIENTS
Billingsley J-K, Nichols JL IMS Health, Plymouth Meeting, PA, USA Length of therapy can affect clinical outcomes as well as total healthcare costs that patients incur. Understanding which factors influence length of therapy can be a major step in managing treatment. OBJECTIVE: To identify factors affecting length of antidepressant pharmacother-apy for depression patients. METHODS: Using an employer claims database, antidepressant prescription claims of 2,830 depression patients were analyzed for 18 months following their initial prescription for a SSRI/ SNRI, Newer Generation Antidepressant, or Tricyclic/ Tetracyclic in 1996. A wide range of demographic, patient-and prescription-level data were reviewed. Linear regression modeling was implemented to model length of antidepressant pharmacotherapy as a function of explanatory variables. RESULTS: The linear regression model estimated length of prescription therapy as f (age, physician specialty prescribing medication, number of unique drugs prescribed, starting drug therapy class, switch in drug therapy class [yes/no], and number of gaps in therapy). The model was significant (P Ͻ 0.05) overall, as was each regressor. Based on findings, the following inferences can be made: (1) older patients underwent longer therapy; (2) patients treated by a psychologist/ neurologist or both a primary care physician and a psychologist/neurologist underwent longer therapy than patients treated by primary care physicians exclusively; patients treated by other physician specialties underwent shorter therapy; (3) each additional, unique drug prescribed resulted in longer total therapy; (4) patients initially treated with SSRIs/SNRIs had longer therapy than patients initially treated with other antidepressant categories; and (5) each additional gap in therapy resulted in progressively longer therapy. CONCLUSION: A positive relationship was observed between the length of patient's antidepressant pharmacotherapy and a number of factors. A thorough understanding and management of these factors could lead to improved patient outcomes.
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TREATMENT OF CHILDHOOD DEPRESSION IN A MANAGED CARE POPULATION
McLaughlin T 1 , Yazdani C 1 , Hansen J 1 , Margraf T 2 1 NDC Health Information Services, Phoenix, AZ, USA; 2 PharMetrics, Inc., Boston, MA, USA OBJECTIVE: To assess the treatment of childhood depression in a managed care population. METHODS: All subjects contained within Pharmetric's Integrated Outcomes database possessing a diagnosis of depression (ICD-9-CM ϭ 296.2, 296.3, 300.4, 311) during 1997-98, who were between 6-18 years of age at the time of diagnosis and were continuously enrolled for more than 1 year, were eligible for study inclusion. Utilization of psychotherapy and pharmacotherapy during the 1-year period following initial diagnosis was measured, as was depression-related hospitalization. These measures were compared across age categories (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) and gender, and hospitalization rates were compared across psychotherapy and pharmacotherapy cohorts. RESULTS: 461 patients met the inclusion criteria. The mean age was 15.4 years and 51.4% of the sample was female. 96.5% of patients received some type of pharmacotherapy, while only 214 (46.4%) subjects received psychotherapy.
